Literature DB >> 7352721

The spectrum of cardiac defects in the Ehlers-Danlos syndrome, types I and III.

C V Leier, T D Call, P K Fulkerson, C F Wooley.   

Abstract

Nineteen patients with types I and III Ehlers-Danlos syndrome were hospitalized at our institution between 1973 and 1978. Chest roentgenogram, electrocardiogram, and echocardiogram were done; 11 patients underwent cardiac catheterization. Thirty-five cardiac or great vessel abnormalities were detected. Fifteen patients had nitral valve prolapse; six also had tricuspid valve prolapse. Dilatation of the aortic root or extasia of the sinuses of Valsalva, or both, occurred in six patients. Dilatation of the pulmonary artery and annulus caused pulmonary regurgitation in one patient. Congenital heart defects included bicuspid aortic valve (two), pulmonary valvular stenosis (one), ventricular septal defect (two), and an atrial septal defect (one). The apparent high prevalence of cardiovascular abnormalities in hospitalized patients with types I and III Ehlers-Danlos syndrome necessitates a careful cardiovascular evaluation. Conversely, Ehlers-Danlos syndrome types I and III should be excluded in patients with mitral or tricuspid valve prolapse, great vessel dilatation, and congenital heart defects.

Entities:  

Mesh:

Year:  1980        PMID: 7352721     DOI: 10.7326/0003-4819-92-2-171

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

Review 1.  The aortic root: structure, function, and surgical reconstruction.

Authors:  M J Underwood; G El Khoury; D Deronck; D Glineur; R Dion
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

2.  Heart rate, conduction and ultrasound abnormalities in adults with joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type.

Authors:  Filippo Camerota; Marco Castori; Claudia Celletti; Marco Colotto; Silvia Amato; Alessandra Colella; Mario Curione; Chiara Danese
Journal:  Clin Rheumatol       Date:  2014-04-22       Impact factor: 2.980

3.  Dilated aortic root and severe aortic regurgitation causing dilated cardiomyopathy in classic Ehlers-Danlos syndrome.

Authors:  Abir Zainal; Mahmoud Nidal Hamad; Syed Yaseen Naqvi
Journal:  BMJ Case Rep       Date:  2016-07-13

4.  Coronary artery vein grafting in a case of Ehlers-Danlos syndrome.

Authors:  A Redington; J McCue; S Lennox
Journal:  Br Heart J       Date:  1984-08

Review 5.  Mitral valve prolapse associated with other disorders. Casual coincidence, common link, or fundamental genetic disturbance?

Authors:  A D Malcolm
Journal:  Br Heart J       Date:  1985-04

Review 6.  The molecular genetics of Marfan syndrome and related disorders.

Authors:  P N Robinson; E Arteaga-Solis; C Baldock; G Collod-Béroud; P Booms; A De Paepe; H C Dietz; G Guo; P A Handford; D P Judge; C M Kielty; B Loeys; D M Milewicz; A Ney; F Ramirez; D P Reinhardt; K Tiedemann; P Whiteman; M Godfrey
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

7.  Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-β1 (TGF-β1) to Orchestrate Second Heart Field Development.

Authors:  Sara L Lewandowski; Harish P Janardhan; Chinmay M Trivedi
Journal:  J Biol Chem       Date:  2015-09-29       Impact factor: 5.157

8.  Mitral valve prolapse and the association with cutaneous mucin infiltration: ("cardiocutaneous mucinosis").

Authors:  Uzma Farooq; Sonal Choudhary; Michael P McLeod; Daniele Torchia; Paolo Romanelli
Journal:  J Clin Aesthet Dermatol       Date:  2013-05

9.  Quantitative structural analysis of collagen in chordae tendineae and its relation to floppy mitral valves and proteoglycan infiltration.

Authors:  P Whittaker; D R Boughner; D G Perkins; P B Canham
Journal:  Br Heart J       Date:  1987-03

Review 10.  Recurrent compartment syndrome in a patient with clinical features of a connective tissue disorder.

Authors:  Brenda D Barajas; Angela Sun; David L Rimoin; Eyal Reinstein
Journal:  Am J Med Genet A       Date:  2013-04-30       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.